QPTFF (Quest PharmaTech) EBIT per Share: $0.02 (TTM As of Jan. 2026)


What is Quest PharmaTech EBIT per Share?

Quest PharmaTech QPTFF EBIT per Share is $0.02 as of Jan. 2026. Among 1,172 Biotechnology companies, Quest PharmaTech ranks worse than 61.09% on this metric.

Quest PharmaTech's EBIT per Share for the three months ended in Jan. 2026 was $0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2026 was $0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 7.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 4.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 22.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Quest PharmaTech's EBIT per Share or its related term are showing as below:

QPTFF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -143.8   Med: -5.05   Max: 62.3
Current: 7.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Quest PharmaTech was 62.30% per year. The lowest was -143.80% per year. And the median was -5.05% per year.

QPTFF's 3-Year EBIT Growth Rate is ranked worse than
61.09% of 1172 companies
in the Biotechnology industry
Industry Median: 15.35 vs QPTFF: 7.20

Quest PharmaTech's EBIT for the three months ended in Jan. 2026 was $2.47 Mil.

Quest PharmaTech  (OTCPK:QPTFF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Quest PharmaTech EBIT per Share Related Terms

Quest PharmaTech EBIT per Share Historical Data

* Premium members only.

The historical data trend for Quest PharmaTech's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest PharmaTech EBIT per Share Chart

Quest PharmaTech Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.40 -0.29 -0.01 -0.01 0.02

Quest PharmaTech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 -0.00 0.01 0.02

Quest PharmaTech EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Quest PharmaTech's EBIT per Share for the fiscal year that ended in Jan. 2026 is calculated as

EBIT per Share(A: Jan. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=3.645/169.129
=0.02

Quest PharmaTech's EBIT per Share for the quarter that ended in Jan. 2026 is calculated as

EBIT per Share(Q: Jan. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=2.473/169.129
=0.01

EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $0.02 mean?
Quest PharmaTech (QPTFF) has a EBIT per Share of $0.02 as of Jan. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Quest PharmaTech and its competitors. According to the industry distribution chart, Quest PharmaTech ranks #716 out of 1172 companies in the Biotechnology industry, placing it in the top 61.1%.
Is Quest PharmaTech's EBIT per Share too high?
Quest PharmaTech's current EBIT per Share is $0.02. The Biotechnology industry median EBIT per Share is 15.35. Quest PharmaTech's value of $0.02 is 99.9% below this industry median. Based on the distribution chart, Quest PharmaTech ranks #716 out of 1172 companies in the Biotechnology industry, which is below the industry midpoint.
How does Quest PharmaTech's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quest PharmaTech ranks #716 out of 1172 companies for EBIT per Share. This places Quest PharmaTech in the lower half of its industry. The industry median EBIT per Share is 15.35. Quest PharmaTech's value of $0.02 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest PharmaTech's current EBIT per Share of $0.02 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Quest PharmaTech and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest PharmaTech's current EBIT per Share is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest PharmaTech stock overvalued right now?
Quest PharmaTech (QPTFF) has a current EBIT per Share of $0.02. The current EBIT per Share is $0.02 and 99.9% below the Biotechnology industry median of 15.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Quest PharmaTech (QPTFF), the current EBIT per Share is $0.02 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quest PharmaTech Business Description

Other Exchanges QPT:Canada
Address 4342- 97 Street NW, Edmonton, AB, CAN, T6E 5R9
Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.